Extended Data Fig. 9: TCR^A2-2 T cells eliminate patient-derived endometrial adenocarcinoma xenografted tumors in a mouse model and persist in peripheral blood in vivo.

a, b, Gating strategy used in Fig. 5a to identify viable tumor cells: (a) CRC CD3⁻, eGFP⁺ cells and (b) EAC EpCAM⁺, CD24⁺ cells in single cell suspensions of organoids following coculture with TCR-T cells. Gates for beads used to determine absolute counts are shown in left plots (FSC versus SSC). c, Tumor volume (mm³) measured by caliper at indicated time points after implantation of EAC PDX fragments. Each line represents an individual mouse. d–f, Percentage of (d) hCD45⁺ among all CD45⁺ cells (both mCD45⁺ and hCD45⁺), (e) hCD8⁺ among hCD3⁺hCD45⁺, and (f) mTCRβ⁺ among hCD45⁺ hCD8⁺ in mouse PB at indicated days after T cell injection in mice treated with TCR^A2-2 (top) or TCR^A24 (bottom).

Source data